loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Dapansutrile

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Dapansutrile

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Olatec to Conduct a Phase 2 Trial with its NLRP3 Inhibitor, Dapansutrile
    Olatec to Conduct a Phase 2 Trial with its NLRP3 Inhibitor, Dapansutrile

    20 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240220762945/en

    BUSINESSWIRE
    20 Feb 2024
    Share Share
    Olatec Announces High-Impact Coverage of Dapansutrile
    Olatec Announces High-Impact Coverage of Dapansutrile

    15 Feb 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220215005998/en

    BUSINESSWIRE
    15 Feb 2022
    Share Share
    Olatec Therapeutics’ Dapansutrile, a Selective NLRP3 Inhibitor
    Olatec Therapeutics’ Dapansutrile, a Selective NLRP3 Inhibitor

    29 Dec 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201229005039/en/Olatec-Therapeutics%E2%80%99-Lead-Compound-Dapansutrile-a-Selective-NLRP3-Inhibitor-Prevents-the-Inflammatory-Response-and-Restores-Cognitive-and-Behavioral-Deficits-in-a-Mouse-Model-of-Alzheimer%E2%80%99s-Disease

    BUSINESSWIRE
    29 Dec 2020
    Share Share